Fearon Nkechi J, Benfante Nicole, Assel Melissa, Chesnut Gregory T, Vickers Andrew, Levine Marcia, Broach Vance, Simon Brett A, Twersky Rebecca, Laudone Vincent P
Jt Comm J Qual Patient Saf. 2020 Jul;46(7):410-416. doi: 10.1016/j.jcjq.2020.04.004. Epub 2020 May 17.
Overprescribing of opioids after surgery contributes to long-term abuse. Evaluating opioid prescription patterns and patient-reported opioid use offers an evidence-based method to identify potential overprescription. This quality improvement initiative aimed to reduce and standardize opioid prescriptions upon discharge from an ambulatory oncologic surgery center and evaluate the effect of this change on patients' subsequent opioid use and reported pain.
Between March 2018 and January 2019, consecutive opioid-naïve patients aged ≥ 18 years who underwent robotic or laparoscopic hysterectomy, radical prostatectomy, or partial nephrectomy, or total mastectomy with or without immediate reconstruction were surveyed 7-10 days postoperatively. Data collected in the pre- (n = 551) and post-standardization (n = 480) cohorts included perception of pain relief, opioids prescribed (verified by electronic medical record review) and consumed, and refills received.
Pre-standardization, the median opioid prescription at discharge was 20 pills (interquartile range [IQR] 20-28) or 140 oral morphine milligram equivalents (MME) (IQR 100-150). Median opioid consumption was 2 pills (IQR 0-7) or 10 MME (IQR 0-40) among all services. Opioid prescriptions were later standardized to 7, 8, and 10 pills (35, 40, and 75 MME), in the gynecology, urology, and breast services, respectively. The change was not associated with an increase in reported pain. Refill requests increased postintervention across all surgeries from 4.4% to 7.7%, with the largest increase among patients who underwent breast surgery.
The number of opioid pills given at discharge to patients undergoing ambulatory or short-stay cancer surgery can safely be reduced.
手术后阿片类药物的过度处方会导致长期滥用。评估阿片类药物的处方模式以及患者报告的阿片类药物使用情况,为识别潜在的过度处方提供了一种基于证据的方法。这项质量改进计划旨在减少并规范门诊肿瘤手术中心出院时的阿片类药物处方,并评估这一变化对患者后续阿片类药物使用及报告疼痛的影响。
在2018年3月至2019年1月期间,对年龄≥18岁、首次使用阿片类药物且接受机器人或腹腔镜子宫切除术、根治性前列腺切除术、部分肾切除术或有或无即刻重建的全乳切除术的患者,在术后7 - 10天进行调查。在标准化前(n = 551)和标准化后(n = 480)队列中收集的数据包括疼痛缓解的感知、处方(通过电子病历审查核实)和使用的阿片类药物以及收到的续方。
标准化前,出院时阿片类药物的处方中位数为20片(四分位间距[IQR] 20 - 28)或140口服吗啡毫克当量(MME)(IQR 100 - 150)。所有手术中阿片类药物的使用中位数为2片(IQR 0 - 7)或10 MME(IQR 0 - 40)。在妇科、泌尿科和乳腺科服务中,阿片类药物处方后来分别标准化为7、8和10片(35、40和75 MME)。这一变化与报告疼痛的增加无关。所有手术的续方请求在干预后从4.4%增加到7.7%,其中接受乳腺手术的患者增加最多。
对于接受门诊或短期癌症手术的患者,出院时给予的阿片类药物片数可以安全减少。